Request Free Sample ×
Myasthenia Gravis Market Research Report – Global Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Myasthenia Gravis Market

ID: MRFR/HC/5800-CR
200 Pages
Rahul Gotadki
Last Updated: March 31, 2026

Myasthenia Gravis Market Research Report: Size, Share, Trend Analysis By Disease Type (Acetylcholine Receptor Antibody Positive Myasthenia Gravis, Muscle-Specific Kinase Antibody Positive Myasthenia Gravis, Seronegative Myasthenia Gravis), By Treatment Type (Anticholinesterase Agents, Immunosuppressants, Intravenous Immunoglobulin, Plasmapheresis, Thymectomy), By Route of Administration (Oral, Intravenous, Subcutaneous), By End Users (Hospitals, Specialty Clinics, Homecare Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Myasthenia Gravis Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Myasthenia Gravis Market Summary

As per MRFR analysis, the Myasthenia Gravis Market Size was estimated at 1395.16 USD Million in 2024. The Myasthenia Gravis industry is projected to grow from 1497.29 USD Million in 2025 to 3034.75 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 7.32% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Myasthenia Gravis market is poised for growth driven by innovative therapies and increasing awareness.

  • The emergence of novel therapeutics is reshaping treatment paradigms in the Myasthenia Gravis market.
  • North America remains the largest market, while Asia-Pacific is recognized as the fastest-growing region.
  • Anticholinesterase inhibitors dominate the market, whereas monoclonal antibodies are experiencing rapid growth.
  • The rising prevalence of Myasthenia Gravis and advancements in treatment options are key drivers of market expansion.

Market Size & Forecast

2024 Market Size 1395.16 (USD Million)
2035 Market Size 3034.75 (USD Million)
CAGR (2025 - 2035) 7.32%

Major Players

Roche (CH), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Pfizer (US), Merck & Co. (US), Amgen (US), Eisai (JP), AstraZeneca (GB)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Myasthenia Gravis Market Trends

The Myasthenia Gravis Market is currently experiencing notable developments driven by advancements in treatment options and increased awareness of the condition. As healthcare professionals and researchers delve deeper into the complexities of this autoimmune disorder, innovative therapies are emerging, which may enhance patient outcomes. The growing understanding of the underlying mechanisms of Myasthenia Gravis is likely to foster the development of targeted therapies, potentially transforming the treatment landscape. Furthermore, the rising prevalence of this condition is prompting healthcare systems to allocate more resources towards research and patient care, indicating a shift in focus towards improving quality of life for affected individuals. A significant driver of this expansion is the diversifying myasthenia gravis treatment market, which is benefiting from a robust pipeline of biologics and targeted therapies that address previous gaps in patient care.

In addition, the Myasthenia Gravis Market appears to be influenced by collaborative efforts among pharmaceutical companies, academic institutions, and patient advocacy groups. These partnerships may facilitate the sharing of knowledge and resources, ultimately leading to more effective treatment strategies. The increasing emphasis on personalized medicine suggests that future therapies could be tailored to individual patient profiles, enhancing efficacy and minimizing side effects. Overall, the Myasthenia Gravis Market is poised for growth, driven by innovation, collaboration, and a commitment to improving patient care.

Emergence of Novel Therapeutics

The Myasthenia Gravis Market is witnessing a surge in the development of innovative treatment options. Researchers are exploring various therapeutic avenues, including monoclonal antibodies and gene therapies, which may offer more effective management of symptoms. This trend indicates a shift towards personalized medicine, where treatments are tailored to individual patient profiles, potentially improving overall efficacy.

Increased Awareness and Diagnosis

There is a growing recognition of Myasthenia Gravis among healthcare professionals and the general public. Enhanced awareness campaigns and educational initiatives are likely contributing to earlier diagnosis and intervention. This trend may lead to improved patient outcomes, as timely treatment can significantly mitigate the impact of the disease.

Collaborative Research Initiatives

The Myasthenia Gravis Market is benefiting from collaborative efforts among various stakeholders, including pharmaceutical companies, research institutions, and patient advocacy groups. These partnerships are fostering innovation and accelerating the development of new therapies. Such collaborations may enhance the overall understanding of the disease and lead to more effective treatment strategies.

Myasthenia Gravis Market Drivers

Increasing Prevalence of Myasthenia Gravis

The Global Myasthenia Gravis Market Industry is witnessing a notable increase in the prevalence of myasthenia gravis, a chronic autoimmune disorder characterized by weakness in the skeletal muscles. Current estimates suggest that the incidence rate is approximately 20 cases per 100,000 people, with a higher prevalence observed in women, particularly those aged 20 to 40. This rising incidence is likely to drive demand for innovative therapies and treatment options, contributing to the market's growth. As the population ages, the number of individuals affected by this condition is expected to rise, further emphasizing the need for effective management strategies within the Global Myasthenia Gravis Market Industry.

Market Segment Insights

By Treatment Type: Anticholinesterase Inhibitors (Largest) vs. Monoclonal Antibodies (Fastest-Growing)

Among the treatment types for Myasthenia Gravis, Anticholinesterase Inhibitors hold the largest market share, widely utilized for their effectiveness in alleviating symptoms by enhancing neuromuscular transmission. In contrast, Monoclonal Antibodies, while currently a smaller segment in terms of market share, are rapidly gaining traction due to their innovative mechanisms and targeted therapies. Their adoption is anticipated to increase as awareness and research into their benefits grow. The growth trends within the Myasthenia Gravis treatment segment are driven by advancements in drug development and a deeper understanding of the disease mechanisms. Immunosuppressants and Intravenous Immunoglobulin are expected to continue playing significant roles as cornerstones of treatment. The increasing prevalence of Myasthenia Gravis and rising investment in biopharmaceuticals are anticipated to propel both established and emerging treatment types forward, emphasizing the varying dynamics within this segment.

Anticholinesterase Inhibitors (Dominant) vs. Monoclonal Antibodies (Emerging)

Anticholinesterase Inhibitors, such as Pyridostigmine, remain the dominant force in the treatment of Myasthenia Gravis due to their long-standing efficacy in improving muscle strength and endurance for patients. This group of medications works by inhibiting the breakdown of acetylcholine, thereby enhancing neuromuscular transmission. On the other hand, Monoclonal Antibodies represent an emerging class of treatments that are gaining significance in the market. These therapies, which include agents like Eculizumab, offer targeted mechanisms to modulate the immune response more precisely. The rising adoption of such therapies indicates a shift toward personalized medicine in treating Myasthenia Gravis, potentially providing benefits for patients who do not respond adequately to traditional therapies.

By Disease Severity: Severe (Largest) vs. Moderate (Fastest-Growing)

In the Myasthenia Gravis Market, the distribution of disease severity segments reveals that Severe cases dominate the myasthenia gravis market landscape, accounting for the largest share. This segment's prominence is attributed to the heightened medical requirement for therapies and management options suited for patients experiencing significant symptoms. Following this, Moderate disease severity showcases a rapidly increasing market presence, driven by the rising awareness of Myasthenia Gravis and its treatment options among both healthcare providers and patients, contributing to the expansion of this segment.

Moderate (Dominant) vs. Crisis (Emerging)

The Moderate disease severity segment holds a dominant position in the Myasthenia Gravis Market, characterized by manageable yet impactful symptoms that necessitate ongoing treatment and monitoring. This segment sees substantial patient engagement due to the balance of severity, which allows for a variety of treatment options to be explored. In contrast, the Crisis segment is emerging as a noteworthy category as awareness increases regarding acute exacerbation episodes that require immediate medical attention. This growing recognition heralds potential innovations in treatment protocols and care strategies that address the urgent needs of Crisis patients while enhancing overall disease management.

By Patient Demographics: Age (Largest) vs. Gender (Fastest-Growing)

In the Myasthenia Gravis market, age demographics significantly influence the prevalence and severity of the disease. The majority of the patient population is over 50 years old, accounting for a substantial percentage of diagnosed cases. This age group is largely a result of the progressive nature of Myasthenia Gravis, which commonly develops after mid-life. Conversely, the younger demographic, particularly those aged 20 to 40, shows increasing diagnosis rates, indicating a growing recognition of the disease among younger patients. Gender demographics reveal important insights, as women, particularly in the age group of 30 to 50, are diagnosed more frequently than men. However, recent trends show that the incidence of Myasthenia Gravis among men is increasing, making it one of the fastest-growing segments in this market. This shift could be attributed to raised awareness and improved diagnostic capabilities, enabling better identification of cases among male patients who previously went undiagnosed.

Age Group: 50+ (Dominant) vs. Gender: Male (Emerging)

The 50+ age group is the dominant demographic in the Myasthenia Gravis market, as this cohort is most affected by the disease due to its progressive nature. Patients in this age bracket often experience more severe manifestations and complications, which influences their healthcare needs and treatment options. Meanwhile, the male demographic is emerging as a significant segment of the patient population. Increased recognition and diagnosis of Myasthenia Gravis in younger males can be linked to advocacy and awareness efforts that spotlight atypical symptoms. These men may have different treatment responses and challenges compared to their female counterparts, indicating the need for tailored therapeutic approaches.

By Administration Route: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

In the Myasthenia Gravis market, the administration route segment showcases a diverse range of options, with intravenous (IV) administration leading in market share. This dominance is primarily due to the rapid onset of action and the ability to deliver larger doses, catering to severe cases effectively. Subsequent options like oral and subcutaneous routes are also significant, but they cater to specific patient preferences and clinical scenarios, which can influence their market impact. Furthermore, subcutaneous administration is gaining traction, being favored for its user-friendly nature and convenience, especially among patients seeking at-home treatment options.

Intravenous (Dominant) vs. Subcutaneous (Emerging)

The intravenous administration route remains the dominant choice for delivering treatments in the Myasthenia Gravis market, primarily due to its efficiency in drug absorption and immediate therapeutic effect. It is particularly suited for acute management, where quick action is necessary. In contrast, the subcutaneous route is emerging as a favorable alternative, appealing to patients looking for convenience and reduced frequency of hospital visits. Subcutaneous treatments allow for at-home administration, thereby enhancing patient compliance and comfort. Both routes present unique benefits, with intravenous therapy being a staple for acute episodes, while subcutaneous therapies pave the way for chronic management.

By Healthcare Setting: Hospital (Largest) vs. Outpatient Clinic (Fastest-Growing)

In the Myasthenia Gravis market, the distribution of healthcare settings reflects varied preferences among patients and practitioners. Hospitals hold a significant market share, providing comprehensive care and advanced treatment options for severe cases of Myasthenia Gravis. Outpatient clinics, however, are rapidly gaining traction as patients increasingly seek flexible treatment options for ongoing management outside traditional hospital settings. The growth of these clinics points toward a shift in patient preferences toward more accessible and cost-effective solutions.

Hospital (Dominant) vs. Outpatient Clinic (Emerging)

Hospitals represent the dominant healthcare setting for managing Myasthenia Gravis due to their capacity for delivering complex and multi-disciplinary care. They are equipped with specialized medical teams and technologies necessary for diagnosing and managing the complications of the disease. On the other hand, outpatient clinics are emerging as an alternative for patients preferring routine follow-ups and therapies without hospital stays. These clinics offer convenience, improved patient engagement, and can serve as effective long-term management sites, especially for less severe cases where immediate hospital intervention is not necessary.

Get more detailed insights about Myasthenia Gravis Market
Request Free Sample

Regional Insights

North America : Market Leader in Myasthenia Gravis

North America is poised to maintain its leadership in the Myasthenia Gravis market, holding a significant market share of $700.0M in 2024. The region's growth is driven by increasing prevalence rates, advancements in treatment options, and supportive regulatory frameworks. A significant portion of this growth is attributed to the expansion of the US myasthenia gravis market, which benefits from high healthcare expenditure and a rapid adoption rate of novel biologics. The demand for innovative therapies is further fueled by rising awareness and improved diagnostic capabilities, making it a key player in the global landscape. The competitive landscape in North America is characterized by the presence of major pharmaceutical companies such as Roche, Bristol-Myers Squibb, and Pfizer. These companies are actively engaged in research and development to introduce novel therapies. The U.S. remains the leading country, supported by a robust healthcare infrastructure and favorable reimbursement policies, ensuring continued investment in Myasthenia Gravis treatments.

Europe : Emerging Market with Growth Potential

Europe is witnessing a growing Myasthenia Gravis market, valued at $400.0M in 2024. The region benefits from a strong regulatory environment that encourages innovation and access to new therapies. Increased awareness and early diagnosis are driving demand, alongside a rise in clinical trials aimed at developing effective treatments. The European Medicines Agency (EMA) plays a crucial role in facilitating market entry for new drugs, enhancing patient access to therapies. Leading countries in Europe include Germany, France, and the UK, where healthcare systems are increasingly prioritizing neuromuscular disorders. Ongoing clinical research and high treatment adoption rates are significant drivers for the UK myasthenia gravis market, contributing to the overall regional expansion. Key players like Novartis and Sanofi are investing in research to expand their portfolios. The competitive landscape is evolving, with a focus on personalized medicine and biologics, positioning Europe as a significant player in the Myasthenia Gravis market.

Asia-Pacific : Emerging Powerhouse in Healthcare

The Asia-Pacific region is emerging as a significant player in the Myasthenia Gravis market, currently valued at $250.0M in 2024. Factors such as increasing healthcare expenditure, rising awareness of neuromuscular disorders, and a growing aging population are driving market growth. The expansion of the China myasthenia gravis market is particularly noteworthy, as increased government support and the introduction of novel biologics are significantly improving patient access to advanced care. Regulatory bodies are also becoming more supportive of new drug approvals, which is crucial for expanding treatment options in this region. Countries like Japan, China, and Australia are leading the charge, with a growing number of clinical trials and research initiatives. Key players such as Eisai and Amgen are focusing on developing innovative therapies tailored to the needs of the region. The competitive landscape is evolving, with an emphasis on collaboration between pharmaceutical companies and healthcare providers to enhance patient outcomes and access to treatments.

Middle East and Africa : Developing Market with Challenges

The Middle East and Africa region represents a nascent market for Myasthenia Gravis, valued at $45.16M in 2024. The growth is hindered by limited healthcare infrastructure and awareness of the disease. However, increasing investment in healthcare and initiatives to improve access to treatments are beginning to change the landscape. The steady expansion of healthcare infrastructure in Gulf nations is expected to bolster the GCC myasthenia gravis market, creating new opportunities for specialized diagnostic and therapeutic services. Regulatory bodies are working to streamline processes for drug approvals, which is essential for market growth. Countries like South Africa and the UAE are at the forefront, with efforts to enhance healthcare services and patient education. The presence of global players is limited, but companies are starting to explore opportunities in this region. The competitive landscape is gradually evolving, with a focus on partnerships and collaborations to address the unique challenges faced in the Middle East and Africa.

Myasthenia Gravis Market Regional Image

Key Players and Competitive Insights

The Myasthenia Gravis Market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for innovative therapies. Key players such as Roche (CH), Bristol-Myers Squibb (US), and Novartis (CH) are actively shaping the market through strategic initiatives focused on research and development, partnerships, and regional expansion. Roche (CH) has positioned itself as a leader in the market by investing heavily in clinical trials aimed at developing novel therapies, while Bristol-Myers Squibb (US) emphasizes strategic collaborations to enhance its product pipeline. Novartis (CH) is also notable for its commitment to innovation, particularly in gene therapies, which could redefine treatment paradigms in the near future. The competitive structure of the Myasthenia Gravis Market appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. This trend is indicative of a broader strategy among key players to strengthen their market positions while responding to the unique needs of various regional markets. The collective influence of these companies is shaping a competitive environment that prioritizes innovation and responsiveness to patient needs. In November 2025, Roche (CH) announced the initiation of a pivotal Phase III clinical trial for its novel monoclonal antibody targeting Myasthenia Gravis. This strategic move underscores Roche's commitment to advancing treatment options and potentially capturing a larger market share. The trial's outcomes could significantly impact the company's positioning, especially if the therapy demonstrates superior efficacy compared to existing treatments. In October 2025, Bristol-Myers Squibb (US) entered into a strategic partnership with a biotechnology firm to co-develop a new immunotherapy for Myasthenia Gravis. This collaboration is expected to leverage both companies' strengths in research and development, potentially accelerating the timeline for bringing innovative therapies to market. Such partnerships are increasingly vital in a landscape where speed to market can determine competitive advantage. In September 2025, Novartis (CH) launched a new digital platform aimed at enhancing patient engagement and adherence to treatment regimens for Myasthenia Gravis. This initiative reflects a growing trend towards digitalization in healthcare, where technology is utilized to improve patient outcomes. By integrating digital tools into its strategy, Novartis is likely positioning itself as a forward-thinking leader in the market. As of December 2025, the Myasthenia Gravis Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming increasingly important, as companies recognize the need to pool resources and expertise to navigate the complexities of the market. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies approach market entry and product development, ultimately benefiting patients through improved treatment options.

Key Companies in the Myasthenia Gravis Market include

Industry Developments

  • Q4 2024: UCB receives FDA approval for ZILBRYSQ (zilucoplan) for generalized myasthenia gravis in adults UCB announced that the U.S. FDA approved ZILBRYSQ (zilucoplan), a once-daily subcutaneous peptide inhibitor, for the treatment of generalized myasthenia gravis in adult patients, marking a significant regulatory milestone for the company.
  • Q2 2024: Argenx receives European Commission approval for Vyvgart for generalized myasthenia gravis Argenx secured European Commission approval for its drug Vyvgart (efgartigimod alfa) for the treatment of generalized myasthenia gravis, expanding its market presence in Europe.
  • Q1 2024: Alexion, AstraZeneca Rare Disease, announces positive Phase 3 results for Ultomiris in myasthenia gravis Alexion, AstraZeneca Rare Disease, reported positive Phase 3 clinical trial results for Ultomiris (ravulizumab) in patients with generalized myasthenia gravis, paving the way for potential regulatory submissions.
  • Q2 2024: UCB partners with Roche to co-develop new monoclonal antibody for myasthenia gravis UCB and Roche announced a strategic partnership to co-develop a next-generation monoclonal antibody targeting refractory myasthenia gravis, aiming to address unmet clinical needs.
  • Q3 2024: Argenx raises $400 million in public offering to expand myasthenia gravis drug portfolio Argenx completed a $400 million public offering to support the expansion of its myasthenia gravis drug portfolio and fund ongoing clinical trials.
  • Q2 2025: Descartes-08 receives FDA Fast Track designation for myasthenia gravis Descartes-08, a novel RNA-engineered cell therapy, was granted Fast Track designation by the FDA for the treatment of generalized myasthenia gravis, accelerating its development timeline.
  • Q1 2025: AstraZeneca opens new manufacturing facility for myasthenia gravis biologics in the US AstraZeneca inaugurated a new state-of-the-art manufacturing facility in the United States dedicated to producing biologics for rare diseases, including myasthenia gravis.
  • Q2 2024: Immunovant announces $230 million Series C funding to advance anti-FcRn antibody for myasthenia gravis Immunovant raised $230 million in Series C funding to accelerate the development of its anti-FcRn antibody, IMVT-1402, for the treatment of myasthenia gravis.
  • Q3 2024: Janssen submits BLA to FDA for nipocalimab in generalized myasthenia gravis Janssen, a Johnson & Johnson company, submitted a Biologics License Application (BLA) to the FDA for nipocalimab, a monoclonal antibody for the treatment of generalized myasthenia gravis.
  • Q2 2025: Telitacicept receives conditional approval in China for myasthenia gravis Telitacicept, developed by RemeGen, received conditional approval from Chinese regulators for the treatment of myasthenia gravis, marking its first market entry.
  • Q1 2025: UCB appoints new Head of Rare Disease Division to lead myasthenia gravis strategy UCB announced the appointment of a new Head of Rare Disease Division to oversee its global strategy for myasthenia gravis and other rare autoimmune disorders.
  • Q4 2024: CRD-1 initiates Phase 2 trial for seronegative myasthenia gravis patients CRD-1, a novel therapeutic candidate, began Phase 2 clinical trials targeting seronegative myasthenia gravis patients, addressing a significant unmet need in the market.

Future Outlook

Myasthenia Gravis Market Future Outlook

The Myasthenia Gravis Market is projected to grow at a 7.32% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing awareness.

New opportunities lie in:

  • Development of targeted biologics for personalized treatment plans. Expansion of telehealth services for remote patient monitoring. Investment in AI-driven diagnostic tools for early detection.

By 2035, the Myasthenia Gravis Market is expected to achieve substantial growth and innovation.

Market Segmentation

Myasthenia Gravis Market Treatment Type Outlook

  • Anticholinesterase Inhibitors
  • Immunosuppressants
  • Monoclonal Antibodies
  • Plasmapheresis
  • Intravenous Immunoglobulin

Myasthenia Gravis Market Disease Severity Outlook

  • Mild
  • Moderate
  • Severe
  • Crisis
  • Remission

Myasthenia Gravis Market Healthcare Setting Outlook

  • Hospital
  • Outpatient Clinic
  • Home Healthcare
  • Long-term Care Facility
  • Specialized Treatment Center

Myasthenia Gravis Market Administration Route Outlook

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular
  • Topical

Myasthenia Gravis Market Patient Demographics Outlook

  • Age
  • Gender
  • Ethnicity
  • Socioeconomic Status
  • Geographic Distribution

Report Scope

MARKET SIZE 2024 1395.16(USD Million)
MARKET SIZE 2025 1497.29(USD Million)
MARKET SIZE 2035 3034.75(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.32% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Roche (CH), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Pfizer (US), Merck & Co. (US), Amgen (US), Eisai (JP), AstraZeneca (GB)
Segments Covered Treatment Type, Disease Severity, Patient Demographics, Administration Route, Healthcare Setting
Key Market Opportunities Advancements in targeted therapies and personalized medicine enhance treatment options in the Myasthenia Gravis Market.
Key Market Dynamics Rising demand for innovative therapies drives competitive dynamics in the Myasthenia Gravis market.
Countries Covered North America, Europe, APAC, South America, MEA

Market Highlights

FAQs

What is the projected market valuation for the Myasthenia Gravis Market in 2035?

The projected market valuation for the Myasthenia Gravis Market in 2035 is 3034.75 USD Million.

What was the overall market valuation for the Myasthenia Gravis Market in 2024?

The overall market valuation for the Myasthenia Gravis Market in 2024 was 1395.16 USD Million.

What is the expected CAGR for the Myasthenia Gravis Market during the forecast period 2025 - 2035?

The expected CAGR for the Myasthenia Gravis Market during the forecast period 2025 - 2035 is 7.32%.

Which companies are considered key players in the Myasthenia Gravis Market?

Key players in the Myasthenia Gravis Market include Roche, Bristol-Myers Squibb, Novartis, Sanofi, Pfizer, Merck & Co., Amgen, Eisai, and AstraZeneca.

What treatment type segment had the highest valuation in the Myasthenia Gravis Market?

The Immunosuppressants segment had the highest valuation, ranging from 450.0 to 950.0 USD Million.

How does the market segment by disease severity categorize patients?

The market segment by disease severity categorizes patients into Mild, Moderate, Severe, Crisis, and Asymptomatic, with Severe patients valued between 418.49 and 910.44 USD Million.

What is the valuation range for the Intravenous administration route in the Myasthenia Gravis Market?

The valuation range for the Intravenous administration route is between 500.0 and 1100.0 USD Million.

What demographic factors are considered in the Myasthenia Gravis Market segmentation?

Demographic factors in the Myasthenia Gravis Market segmentation include Age, Gender, Ethnicity, Socioeconomic Status, and Geographic Distribution.

Which healthcare setting segment is projected to have the highest valuation?

The Hospital segment is projected to have the highest valuation, ranging from 500.0 to 1100.0 USD Million.

What is the valuation range for the Monoclonal Antibodies treatment type?

The valuation range for the Monoclonal Antibodies treatment type is between 250.0 and 600.0 USD Million.

Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

Research Approach

 

Secondary Research

The secondary research process involved comprehensive analysis of neurological disorder registries, peer-reviewed neurology journals, clinical trial databases, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Drug Evaluation and Research, European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), National Institute of Neurological Disorders and Stroke (NINDS), Centers for Disease Control and Prevention (CDC) National Center for Chronic Disease Prevention and Health Promotion, National Institutes of Health (NIH) Neurological Institute, National Center for Biotechnology Information (NCBI/PubMed), ClinicalTrials.gov registry, World Health Organization (WHO) Neurological Disorders Program, Myasthenia Gravis Foundation of America (MGFA), Myasthenia Gravis Association (UK), World Muscle Society (WMS), American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), European Federation of Neurological Associations (EFNA), national health ministry reports from key markets, and IQVIA prescription data. These sources were used to collect epidemiology statistics, treatment paradigm shifts, regulatory approval data for monoclonal antibodies (eculizumab, efgartigimod, rozanolixizumab), clinical safety and efficacy studies, patient demographic trends, and competitive landscape analysis for acetylcholinesterase inhibitors, immunosuppressants, IVIG therapies, and emerging FcRn antagonists.

 

Primary Research

To gather both qualitative and quantitative information, the primary research process involved interviewing players from both the supply and demand sides. Members of the supply side included pharmaceutical companies with a focus on neurology, biotech companies working on autoimmune treatments, and companies making plasma-derived products. They also included vice presidents of clinical development, chiefs of regulatory affairs, and commercial directors. Neurologists, immunologists, clinical pharmacists, hospital formulary decision-makers, medical directors of neurology centers, and procurement leads from academic medical centers, community hospitals, and specialty infusion centers were among the demand-side sources. We confirmed drug pipeline timelines (Phase III to commercialization), analyzed treatment adoption patterns, priced and reimbursed novel biologics, and found patterns of switching between symptomatic and disease-modifying therapies. Primary research also validated market segmentation across antibody-positive and seronegative subtypes.

Primary Respondent Breakdown:

By Designation: C-level Primaries (28%), Director Level (42%), Others (30%)

By Region: North America (32%), Europe (29%), Asia-Pacific (34%), Rest of World (5%)

 

Market Size Estimation

Global market valuation was derived through revenue mapping, prescription volume analysis, and procedure data for thymectomy interventions. The methodology included:

Identification of 35+ key manufacturers and developers across North America, Europe, Asia-Pacific, and Latin America, including players in monoclonal antibodies, biosimilars, and generic immunosuppressants

Product mapping across acetylcholinesterase inhibitors (pyridostigmine), chronic immunosuppressants (azathioprine, mycophenolate, tacrolimus), rapid immunotherapies (IVIG, plasmapheresis), and biologics (complement inhibitors, FcRn antagonists, anti-CD20 therapies)

Analysis of reported and modeled annual revenues specific to myasthenia gravis portfolios, including antibody-positive and seronegative patient segment allocations

Coverage of manufacturers representing 75-80% of global market share in 2024 (generics and originators)

Extrapolation using bottom-up (disease prevalence × diagnosis rate × treatment penetration × annual therapy cost by country) and top-down (manufacturer revenue validation across neurology franchises) approaches to derive segment-specific valuations for symptomatic, maintenance, and rescue therapy categories

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓